Tag: Sobi

Sobi received an FDA CRL for NASP in uncontrolled gout over CMC and CMO deficiencies. The clinical data held. The manufacturing system did not.

Jun 29, 2026, 3:38 PM IST By Dr. Akhilesh Vats FDA & Regulatory Intelligence Pharma Market Case Studies

FDA Issues CRL to Sobi for NASP in Uncontrolled Gout

Sobi NASP CRL: FDA Rejected the Control System | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Manufacturing Long Read Pharma Market Case Studies Witfire Elite…